Biocon concludes a Rs 4,500 crore equity fundraise through QIP
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
The company received seven observations in the Form-483
The company received one observation in the Form-483
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
The company received 1 (One) observation in the Form-483
Dilip Shanghvi to continue as the Executive Chairman of the Board
Zydus receives EIR for the API manufacturing facility at Ankleshwar
The partnership combines Boehringer’s expertise in canine cardiology with Eko’s digital stethoscopes and AI algorithms
The acquisition sets up the foundation for a central hub of GMP value-added services and greater access to new customers in the rapidly growing Biopharma market
Subscribe To Our Newsletter & Stay Updated